Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada

Curkendall, Suellen M.; deLuise, Cynthia; Jones, Judith K.; Lanes, Stephan; Stang, Mary Rose; Goehring, Earl L.; She, Dewei

doi:10.1016/j.annepidem.2005.04.008

Cited by 562 publications

(411 citation statements)

References 17 publications

Supporting

Mentioning

343

Contrasting

Unclassified

Order By: Relevance

“…The males are affected more than females. 7 This study also indicates that majority of our patients were male (90%) with the mean age of 57.33 years. This observation agrees with the fact that COPD is common in males and is greater in older age groups.…”

Section: Discussionmentioning

confidence: 72%

A study of clinical profile of patients with chronic obstructive pulmonary disease

Sinha¹,

Nalli²,

Toppo³

2017

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: Chronic morbidity and also deaths are caused by COPD. Once affected by COPD, patients suffer many years together. Some can die before expected life expectancy. It has been estimated that due to constant exposure to risk factor and increased life expectancy, all over the world the prevalence is likely to increase. The objective of the study was to study the clinical profile of patients with chronic obstructive pulmonary disease.Methods: A hospital based cross sectional study was conducted at department of community medicine, Late Baliram Kashyap Memorial Government Medical College, Jagdalpur, Chhattisgarh, India among patients with chronic obstructive pulmonary disease for a period of six months from September 2015 to February 2016. Informed consent was obtained from each patient. Detail clinical history, physical examination to look for nutritional status, spirometry with reversibility was carried out for each and every patient.Results: Age range in our study was 26-75 years. Mean age in COPD patients was 57.13±11.149 years and that of control group was 54.60±13.074 years with male to female ratio 9.71:1 in COPD case and 11.5:1 in control group. Most common symptom in COPD patient was SOB followed by cough, expectoration, and edema and chest pain. mMRC grading in COPD are higher than control group in our study. Smoking in pack year was significantly higher in COPD cases as 69.70± 36.164 and in control group it was 13.84±7.867.Conclusions: COPD was found to be more common in males. Cough was the most common presenting symptom. Smoking was significantly associated with occurrence of COPD.

show abstract

Section: Discussionmentioning

confidence: 72%

A study of clinical profile of patients with chronic obstructive pulmonary disease

Sinha¹,

Nalli²,

Toppo³

2017

Int J Community Med Public Health

View full text Add to dashboard Cite

show abstract

“…The association between respiratory disease and cardiovascular disease is an area of research that has received a great deal of attention in recent years [20][21][22]. The reasons for this association are unclear, but may be related to systemic inflammation, chronic infections, shared risk factors (such as smoking) or other undefined factors [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

Mannino

Thorn²,

Swensen³

et al. 2008

European Respiratory Journal

981

717

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is associated with important chronic comorbid diseases, including cardiovascular disease, diabetes and hypertension.The present study analysed data from 20,296 subjects aged o45 yrs at baseline in the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS). The sample was stratified based on baseline lung function data, according to modified Global Initiative for Obstructive Lung Disease (GOLD) criteria. Comorbid disease at baseline and death and hospitalisations over a 5-yr follow-up were then searched for.Lung function impairment was found to be associated with more comorbid disease. In logistic regression models adjusting for age, sex, race, smoking, body mass index and education, subjects with GOLD stage 3 or 4 COPD had a higher prevalence of diabetes (odds ratio (OR) 1.5, 95% confidence interval (CI) 1.1-1.9), hypertension (OR 1.6, 95% CI 1.3-1.9) and cardiovascular disease (OR 2.4, 95% CI 1.9-3.0). Comorbid disease was associated with a higher risk of hospitalisation and mortality that was worse in people with impaired lung function.Lung function impairment is associated with a higher risk of comorbid disease, which contributes to a higher risk of adverse outcomes of mortality and hospitalisations.

show abstract

“…Esélyhányados 11 493 COPD-s adata alapján arrhythmiára 1,76, anginára 1,61, AMI-ra 1,61, szívelégtelen-ségre 3,84, cardiovascularis mortalitásra 2,07 [63]. Egyéb cardiovascularis mellékhatást kiváltani képes gyógyszerek: teofi llin, adrenerg szerek, szívgyógyszerek [64].…”

Section: Következtetésekunclassified

Van-e cardiovascularis mellékhatásuk az inhalációs antikolinerg szereknek?

Nagy¹

2015

Orvosi Hetilap

View full text Add to dashboard Cite

Az összefoglaló célja az inhalációs antikolinerg szerek cardiovascularis veszélyének tárgyalása krónikus obstruktív tü-dőbetegségben. A tiotropium-használat adatainak néhány metaanalízise felvetette ilyen mellékhatások (arrhythmia, angina, szívinfarktus stb.) fokozott lehetőségét. Az összefoglaló áttekinti a retrospektív adatbázis-feldolgozásokat, a randomizált kontrollcsoportos vizsgálatokat és a klinikai vizsgálatok metaanalíziseit. Az adatbázis-vizsgálatok eredményei inkonzisztensek. A legtöbb klinikai vizsgálatban a cardiovascularis mellékhatások incidenciája azonos volt az aktív kezelésű és a placebocsoportban, jellemzően azoknál a betegeknél is, akik előzőleg cardiovascularis betegségben szenvedtek. A metaanalízisekben kevés a bizonyíték vagy egyáltalán nincs arra nézve, hogy összefüggés van az antikolinergek és a cardiovascularis tünetek között. A szerző áttekinti a humán szív kolinergreceptor-altípusait és funkcióját, a szívműködés ezen receptorok útján történő autonóm szabályozását, ezek lehetséges szerepét és az inhalált antikolinerg szerek farmakokinetikai tulajdonságait. Megállapítja, hogy nincs bizonyíték az inhalációs antikolinerg szerek fokozott cardiovascularis ártalmára. Orv. Hetil., 2015, 156(31), 1246-1252. Kulcsszavak: krónikus obstruktív tüdőbetegség, inhalációs antikolinerg szerek, cardiovascularis szövődmények Are there cardiovascular adverse effects of inhaled anticholinergics?The purpose of this review is to discuss the cardiovascular risk associated with inhaled anticholinergics in chronic obstructive pulmonary disease. Several meta-analyses of data for tiotropium raised the possibility of an increased risk for arrhythmia, angina, myocardial infarction, etc. This review includes the data of retrospective studies of databases using databases, randomized controlled trials, and meta-analyses of clinical trials. The conclusions of studies were inconsistent. In most clinical trials the incidence of cardiovascular adverse events was similar in active treatment and placebo groups, especially in patients with previous cardiovascular diseases. Considering meta-analyses, there is little, if any, evidence for the association between anticholinergics and the development of cardiovascular symptoms. The author discusses the presence and function of cholinergic receptor subtypes in human heart, and cardiac functions controlled by the autonomic nervous system via these receptors, their possible role, and pharmacokinetic properties of inhaled anticholinergics. The author concludes that it is not possible to fi nd evidence of increased cardiovascular harm of inhaled anticholinergics.Keywords: chronic obstructive pulmonary disease, inhaled anticholinergics, adverse cardiovascular events Nagy, L. B. [Are there cardiovascular adverse effects of inhaled anticholinergics?]. Orv. Hetil., 2015, 156(31), 1246-1252. (Beérkezett: 2015 elfogadva: 2015. május 18.) Rövidítések cAMP = ciklikus adenozin-monofoszfát; COPD = krónikus obstruktív tüdőbetegség; FEV1 = forszírozott másodpercvolu-men; ISZB = ischaemiás s...

show abstract

Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada

Cited by 562 publications

References 17 publications

A study of clinical profile of patients with chronic obstructive pulmonary disease

A study of clinical profile of patients with chronic obstructive pulmonary disease

Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD

Van-e cardiovascularis mellékhatásuk az inhalációs antikolinerg szereknek?

Contact Info

Product

Resources

About